Shield is a software-as-a-service (SaaS)-based self-learning fraud prevention solution for e-commerce. It combines latest fraud detection technology with machine learning, predictive analytics, and big data that runs on an optimized risk algorithm to compute the decision for accepting or rejecting each transaction. It was formerly known as CashShield. It was founded in 2008 and is based in Singapore, Singapore.
Shield's Product Videos
ESPs containing Shield
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The device fingerprinting market, also referred to as device intelligence, offers customers a tool for identifying and authenticating devices accessing their systems or platforms. Device fingerprinting involves creating unique digital profiles based on various device attributes such as hardware, software, network configuration, and behavior patterns. This helps enhance security measures by detecti…
Shield's Products & Differentiators
The SHIELD Platform
From superapps and ride-hailing platforms to digital banks and e-commerce companies, the SHIELD Platform protects mobile businesses from all types of fraud and abuse. These include fake accounts, account takeovers, payment fraud, referral & promo abuse, incentive abuse, ad fraud and more. Leveraging world-leading device fingerprinting technology, the SHIELD Platform detects every device showing signs of risky behavior at every step of the user journey - from app installation and registration to cashback and payments.
Research containing Shield
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Shield in 1 CB Insights research brief, most recently on Aug 14, 2023.
Expert Collections containing Shield
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Shield is included in 7 Expert Collections, including Regtech.
Technology that addresses regulatory challenges and facilitates the delivery of compliance requirements. Regulatory technology helps companies and regulators address challenges ranging from compliance (e.g. AML/KYC) automation and improved risk management.
Companies in this collection provide technology that enables consumers and businesses to pay, collect, automate, and settle transfers of currency, both online and at the physical point-of-sale.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
These companies protect organizations from digital threats.
Excludes US-based companies
Digital ID In Fintech
For this analysis, we looked at digital ID companies working in or with near-term potential to work in fintech applications. Startups here are enabling fintech companies to verify government documents, authenticate with biometrics, and combat fraudulent logins.
Shield has filed 21 patents.
Automotive body parts, Automotive styling features, Automotive accessories, Former motor vehicle assembly plants, Pickup trucks
Automotive body parts, Automotive styling features, Automotive accessories, Former motor vehicle assembly plants, Pickup trucks
Latest Shield News
Nov 13, 2023
USA - English Share this article Share toX SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH ), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea. Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and the third-leading cause of cancer-related deaths in South Korea.1,2 Guardant Health's Shield test, which can be used for regular CRC screening in eligible individuals, is an innovative test that can detect cancer in its early stages by analysing circulating tumour DNA (ctDNA), which is produced when tumours shed small pieces of their genetic material into the bloodstream. In the pivotal ECLIPSE study, which enrolled over 20,000 patients, the Shield test achieved 83% sensitivity for the detection of colorectal cancer in average-risk adults in the U.S., with specificity of 90%.3 Early detection is essential to reduce colorectal cancer mortality. Colonoscopy and faecal tests are generally used for early detection, however, compliance rates for these screening tests are low and have remained stagnant since 2014.4 The primary reasons for lack of compliance with CRC screening recommendations include not having any symptoms of CRC, lack of time for a colonoscopy procedure, which requires a few days of preparation, and fear of an invasive colonoscopy procedure.4 Since the launch of the lab-developed version of the Shield test in May 2022, it has shown approximately 90% adherence in a real-world clinical setting, demonstrating the value of blood-based screening to increase adherence to recommended screening protocols.5 "Colorectal cancer rarely has symptoms in its early stages, and by the time symptoms appear, the disease has often progressed considerably. Therefore, early detection through a screening test is critical," said Health Promotion Center of Samsung Medical Center. "The Shield blood test can broaden the range of choices for colorectal cancer screening. We are confident that by introducing a high-quality blood-based screening test, we can meet the needs of both patients and healthcare providers and help improve screening compliance." "We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa. "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw." About the Shield Test The Shield test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumours, called ctDNA. Specifically, the test identifies certain characteristics of the DNA that may indicate the presence of cancer. The clinical performance of the Shield assay in detecting colorectal cancer in average-risk individuals was validated in ECLIPSE, a registrational study that enrolled over 20,000 patients in the U.S. The test demonstrated 83% sensitivity for the detection of colorectal cancer with specificity of 90%. The test also demonstrated 13% sensitivity in detecting advanced adenomas. Shield is commercially available for eligible individuals by prescription only through healthcare professionals. This LDT (Laboratory Developed Test) is intended to be complementary to, and not a replacement for, current recommended CRC screening methods. A negative result does not rule out the presence of cancer. Patients with an abnormal blood-based screening result should be referred for a diagnostic colonoscopic evaluation. More information about the Shield test is available at bloodbasedscreening.com . For more information about the ECLIPSE study ( NCT04136002 ), visit www.clinicaltrials.gov . About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY® tests for advanced stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com or guardanthealthamea.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2022, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. References National Cancer Information Center (NCIC). Cancer in statistics available at https://www.cancer.go.kr/ accessed on 12 October 2023. Chung, et al. Digestive Diseases Week 2023. Abstract #913e available at https://guardanthealth.com/wp-content/uploads/ChungGrady_DDW_Abstract-913e_FINAL.pdf accessed on 12 October 2023 Park B, Lee YY, Song SY, Shin HY, Suh M, Choi KS, Jun JK. Trends of Colorectal Cancer Screening Rates in Korea: Korean National Cancer Screening Survey 2005–2020. Gut and Liver 2022; 16:930-941. https://doi.org/10.5009/gnl210419 Shield LDT internal data on file. Guardant Health, Inc. SOURCE Guardant Health
Shield Frequently Asked Questions (FAQ)
When was Shield founded?
Shield was founded in 2008.
Where is Shield's headquarters?
Shield's headquarters is located at 1 Fifth Avenue, Singapore.
What is Shield's latest funding round?
Shield's latest funding round is Series B.
How much did Shield raise?
Shield raised a total of $25.61M.
Who are the investors of Shield?
Investors of Shield include Tony Fadell, GGV Capital, Tao Zhang, Temasek, Wavemaker Partners and 6 more.
Who are Shield's competitors?
Competitors of Shield include Bureau, DataVisor, Fraud.net, FUGU, CHEQ and 7 more.
What products does Shield offer?
Shield's products include The SHIELD Platform.
Who are Shield's customers?
Customers of Shield include Razer, Alibaba, ShareChat and OMNi.
Compare Shield to Competitors
Forter focuses on fraud prevention and protection in the digital commerce industry. The company offers services such as fraud management, payment optimization, chargeback recovery, identity protection, and abuse prevention, all aimed at increasing revenue, reducing losses, and enhancing the customer experience. It primarily serves the digital commerce industry. It was founded in 2013 and is based in New York, New York.
Sift provides real-time machine learning fraud prevention solutions for online businesses. Its machine-learning software automatically learns and detects fraudulent behavioral patterns and alerts businesses before they or their customers are defrauded. It provides its services in a wide range of industries such as financial technology, retail, payment service providers, and more. It was formerly known as Sift Science. It was founded in 2011 and is based in San Francisco, California.
Signifyd provides e-commerce fraud protection and prevention services. The company offers services, including revenue protection, abuse prevention, and payment compliance, all aimed at maximizing conversion and eliminating fraud and consumer abuse. These services primarily cater to the e-commerce industry. Signifyd was founded in 2011 and is based in San Jose, California.
NS8 is an eCommerce company that provides abuse, fraud, and user experience protection tools. The company uses behavioral analytics, real-time user scoring, and global monitoring to optimize and protect against threats, which give eCommerce merchants insight into their real customers.
SEON Technologies offers end-to-end fraud prevention and detection tools for businesses. Its artificial intelligence (AI) powered system uses data enrichment and machine learning to reduce revenue loss and manual review time. The company was founded in 2017 and is based in London, United Kingdom.
Vesta offers a transaction guarantee platform for online purchases and electronic payment solutions. It is engaged in fraud protection and e-commerce payment solutions that assist online merchants, telcos, payment processors and acquirers optimize revenue by helping eliminate the fear of fraud through a variety of channels, including the internet, mobile phones, retail point of sale, and mobile commerce applications. Vesta was formerly known as Carrier Services. The company was founded in 1995 and is based in Lake Oswego, Oregon.